J 2022

Protection provided by vaccination, booster doses and previous infection against covid-19 infection, hospitalisation or death over time in Czechia

BEREC, Luděk, Martin ŠMÍD, Lenka PŘIBYLOVÁ, Ondřej MÁJEK, Tomáš PAVLÍK et. al.

Basic information

Original name

Protection provided by vaccination, booster doses and previous infection against covid-19 infection, hospitalisation or death over time in Czechia

Authors

BEREC, Luděk (guarantor), Martin ŠMÍD, Lenka PŘIBYLOVÁ (203 Czech Republic, belonging to the institution), Ondřej MÁJEK (203 Czech Republic, belonging to the institution), Tomáš PAVLÍK (203 Czech Republic, belonging to the institution), Jiří JARKOVSKÝ (203 Czech Republic, belonging to the institution), Milan ZAJÍČEK, Jakub WEINER, Tamara BARUSOVÁ and Jan TRNKA

Edition

PLoS ONE, Public Library of Science, 2022, 1932-6203

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30303 Infectious Diseases

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 3.700

RIV identification code

RIV/00216224:14110/22:00126311

Organization unit

Faculty of Medicine

DOI

UT WoS

000844536800079

Keywords in English

COVID 19; SARS CoV 2; Viral vaccines; Vaccines; Czech Republic; Immunity; Vaccination and immunization; Booster doses

Tags

Tags

International impact, Reviewed
Změněno: 4/1/2023 11:16, Mgr. Marie Šípková, DiS.

Abstract

V originále

Studies demonstrating the waning of post-vaccination and post-infection immunity against covid-19 generally analyzed a limited range of vaccines or subsets of populations. Using Czech national health data from the beginning of the covid-19 pandemic till November 20, 2021 we estimated the risks of reinfection, breakthrough infection, hospitalization and death by a Cox regression adjusted for sex, age, vaccine type and vaccination status. Vaccine effectiveness against infection declined from 87% at 0-2 months after the second dose to 53% at 7-8 months for BNT162b2 vaccine, from 90% at 0-2 months to 65% at 7-8 months for mRNA-1273, and from 83% at 0-2 months to 55% at 5-6 months for the ChAdOx1-S. Effectiveness against hospitalization and deaths declined by about 15% and 10%, respectively, during the first 6-8 months. Boosters (third dose) returned the protection to the levels observed shortly after dose 2. In unvaccinated, previously infected individuals the protection against infection declined from 97% after 2 months to 72% at 18 months. Our results confirm the waning of vaccination-induced immunity against infection and a smaller decline in the protection against hospitalization and death. Boosting restores the original vaccine effectiveness. Post-infection immunity also decreases over time.